56 results about "Post stroke" patented technology

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.

A method for treating a patient suffering from loss of muscle control and/or function in a body region after a stroke includes epidurally applying electrical stimulation to a spinocerebellar tract of the patient (e.g., at or above the vertebral level of the spinal cord where the sensory and motor mapping for the body region are located), thereby increasing cortical excitability and facilitating the patient regaining muscle control and/or function in the body region. The method may include using cortical mapping to determine a cortical region having a residual motor response in or near the body region, implanting an electrode in a lateral epidural space, and applying the electrical stimulation in a manner that causes excitability in the cortical region having the residual motor response, wherein the stimulation is applied by the implanted electrode. The method may include exercising the body region while simultaneously applying the electrical stimulation.

The invention provides a system for evaluating hearing-speech rehabilitation training and curative effect of patients with post-stroke dysarthria and a device thereof. The system comprises a patient selecting module (1), an effect evaluating module (2), a training module (3) and a clinical curative effect evaluating module (4). The invention also provides a method for evaluating hearing-speech rehabilitation training and curative effect of patients with post-stroke dysarthria. The method comprises the following steps: selecting patients with post-stroke dysarthria, evaluating before training, training language, evaluating after training and evaluating clinical curative effect. The system and the method are used for training pronunciation and reading in hearing-speech rehabilitation treatment of the patients with post-stroke dysarthria, providing curative effect evaluation, improving pronunciation accuracy degree and continuous pronunciation coordination ability of the patients, subdividing treatment grades according to different conditions of the patients, making individual training schemes and improving pertinence, relieving working strength of hearing-speech rehabilitation therapists and effectively improving the working efficiency and the individual treatment training effect.

This application provides devices for modeling ischemic stroke conditions. The devices can be used to culture neurons and to subject a first population of the neurons to low-oxygen conditions and a second population of neurons to normoxic conditions. The neurons are cultured on a porous barrier, and on the other side of the barrier run one or more fluid-filled channels. By flowing fluid with different oxygen levels through the channels, one can deliver desired oxygen concentrations to the cells nearest those channels.

A method of post-stroke treatment at delayed timepoints with sigma receptor agonists. Sigma receptors are promising targets for neuroprotection following ischemia. One of the key components in the demise of neurons following ischemic injury is the disruption of intracellular calcium homeostasis. The sigma receptor agonist, DTG, was shown to depress [Ca²⁺]_i elevations observed in response to ischemia induced by sodium azide and glucose deprivation. Two sigma receptor antagonists, metaphit and BD-1047, were shown to blunt the ability of DTG to inhibit ischemia-evoked increases in [Ca²⁺]_i. DTG inhibition of ischemia-induced increases in [Ca²⁺]_i was mimicked by the sigma-1 receptor-selective agonists, carbetapentane, (+)-pentazocine and PRE-084, but not by the sigma-2 selective agonist, ibogaine, showing that activation of sigma-1 receptors is responsible for the effects. Activation of sigma receptors can ameliorate [Ca²⁺]_i dysregulation associated with ischemia in cortical neurons, providing neuroprotective properties. The effects of 1,3-di-o-tolyguanidine (DTG), a high affinity sigma receptor agonist, as a potential treatment for decreasing infarct area at delayed time points was further examined in rats. DTG treatment significantly reduced infarct area in both cortical/striatal and cortical/hippocampal regions by >80%, relative to control rats. These findings were confirmed by immunohistochemical experiments using the neuronal marker, mouse anti-neuronal nuclei monoclonal antibody (NeuN), which showed that application of DTG significantly increased the number of viable neurons in these regions. Furthermore, DTG blocked the inflammatory response evoked by MCAO, as indicated by decreases in the number of reactive astrocytes and activated microglia/macrophages detected by immunostaining for glial fibrillary acidic protein (GFAP) and binding of isolectin IB4, respectively. Thus, the sigma receptor-selective agonist, DTG, can enhance neuronal survival when administered 24 hr after an ischemic stroke. In addition, the efficacy of sigma receptors for stroke treatment at delayed time points is likely the result of combined neuroprotective and anti-inflammatory properties of these receptors.

A traditional Chinese medicine composition and fumigating device for treating post-stroke limb numbness based on fumigation means comprises Radix Angelicae Sinensis, Radix Paeoniae Rubra, Radix Rehmanniae Preparata, Rhizoma Chuanxiong, Flos Carthami, Fructus Chaenomelis Lagenariae, Ramulus Mori, Radix Astragali, Herba Lycopodii and Caulis Spatholobi; steam produced by the above herbs is utilized to perform muscular stimulation and pharmaceutical ingredient permeation on limbs of a patient so that the traditional Chinese medicine therapeutic rules of supporting the healthy energy, benefiting qi and nourishing blood, invigorating spleen and soothing liver and dispersing stasis and removing toxin are achieved; the herbs are combined so that the herbs are synergic, thereby enabling effective treatment for post-stroke limb numbness; therefore, treatment effect on post-stroke limb numbness is improved without no side effects produced.

The invention relates to the field of medicine, and discloses a novel application of 3-methoxyl mangiferin in the field of pharmacy, and a medicine composition comprising 3-methoxyl mangiferin. 3-methoxyl mangiferin can promote hippocampus dentate gyrus neuron 5-hydroxytryptamine 1A receptor gene and protein expressions, and can induce neurotrophic effects such as hippocampus remodeling performed by 5-hydroxytryptamine. Therefore, post-stroke hippocampus nerve aregeneratory can be substantially ameliorated, 5-HT re-uptake of nerve presynaptic membrane can be selectively inhibited, 5-HT positive cell expression at hypothalamus can be reduced, exhaustion of 5-HT can be relieved, and anxiety and depression symptoms caused by 5-HT exhaustion can be relieved. Therefore, 3-methoxyl mangiferin can be used in preparing medicines used for treating post-stroke depression.

The invention discloses an application of Tianlou Guizhi decoction in treatment of post-stroke spasm. The decoction comprises the following materials: 15-45 parts of Radix Trichosanthis, 4.5-13.5 parts of Ramulus Cinnamomi, 4.5-13.5 parts of Radix Paeoniae Alba, 3-9 parts of Radix Glycyrrhizae, 4.5-13.5 parts of Rhizoma Zingiberis Recens and6-18 parts of Fructus Jujubae. The decoction has definite curative effect, and facilitates rehabilitation training.

N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide and salts thereof are used for the preparation of medicaments, particularly of pharmaceutical compositions containing it as an active ingredient, for the treatment of neurodegeneration, in particular in post-stroke human patients. The early administration of nefiracetam or its salt in said pharmaceutical compositions after a stroke allows an improvement of the Acivities of Daily Living and the recovery, or at least in improvement in the recovery of, post-stroke patients.

The present invention provides compositions and methods for regulating the BK channel using rottlerin and derivatives thereof. In particular, the present invention provides pharmaceutical compositions for use in treating or preventing BK channel medicated disorders including hypertension and various hyperexcitability disorders. Also provided are compositions and methods for use in post-stroke neuroprotection and in treating or preventing erectile dysfunction. The present invention further provides kits for use in treating or preventing BK channel mediated disorders, comprising the compositions of the present invention.

A tennis skill training device comprising a substantially planar foot placement platform platform having foot placement graphics disposed thereon, the foot placement graphics consisting of a first stance position representing right and left foot positions for a right-handed player proximate a first court position, a second stance position representing right and left foot positions for a right-handed player proximate a second court position, and a first toss target representing a first forward foot post-stroke position for the right-handed player. In some embodiments, the graphics include a third stance position representing right and left foot positions for a left-handed player proximate the first court position, a fourth stance position representing right and left foot positions for the left-handed player proximate the second court position, and a second toss target representing a first forward foot post-stroke position for the left-handed player.

The patent discloses application of a tanshinone IIA nano preparation, shown as in .1 and using O-hydroxyethyl chitosan derivative as an entrapping agent, in drugs to prevent or treat cerebral ischemia, particularly nerve injury due to local cerebral ischemia, and belongs to the technical field of nerve protection drugs. The tanshinone IIA entrapped by a nano carrier can quickly pass through the blood brain barrier. Compared with tanshinone IIA, the tanshinone IIA nano preparation has better blocking action upon nerve injury in acute stage of ischemic brain injury; threshold concentration is far lower than the concentration of tanshinone IIA. In addition, it is discovered that tanshinone IIA can promote healing of post-stroke injury and can play well by stimulating regeneration of post-ischemia endogenous nerves; tanshinone IIA entrapped by the nano carrier is more active than tanshinone IIA with the same dosage. The nano preparation herein can treat stroke-caused injury.

The invention provides a composition for preventing stroke and improving stroke severity and application of the composition. The composition comprises an effective amount of lactobacillus reuteri GMNL-89 and an effective amount of lactobacillus paracasei GMNL-133, wherein the register number of the lactobacillus reuteri GMNL-89 is CCTCC M2011331, and the register number of the lactobacillus paracasei GMNL-133 is CCTCC M207154. The composition can be taken by normal people at ordinary days, is continuously administrated after stroke attack, and has the effects of improving cerebral infarction after stroke, recovering athletic ability and improving intestinal flora.

The invention discloses a traditional Chinese medicine composition used for treating post-stroke limb numbness. The medicine composition is composed of the raw materials of, by weight: 10-12 parts of Mongolian milkvetch root, 4-6 parts of swollen furuncle, 2-4 parts of red peony root, 4-6 parts of panax notoginseng, 2-4 parts of yanhusuo tuber, 5-7 parts of tall gastrodia rhizome, 4-6 parts of tuber fleeceflower root, 2-3 parts of scorpion, 5-7 parts of stiff silkworm, 1-3 parts of lumbricus, 1-3 parts of common heron bill herb, 4-6 parts of leech, 2-4 parts of largeleaf gentian root, 3-4 parts of twotoothed achyranthes root, 9-11 parts of common ducksmeat herb, 8-10 parts of cushaw base, 4-6 parts of borreria stricta, 2-3 parts of bouquet larkspur herb, 4-6 parts of mantis eggcase, 1-3 parts of Japanese peristrophe herb, and 1-3 parts of parthenocissus heterophyllus. The medicine composition provided by the invention has wind-evil-dispelling, refreshing, brain-orifice-unblocking, meridian-dredging, wind-evil-dissipating, swelling-subsiding, menstrual-flow-unblocking, blood-circulation-activating, blood-vessel-softening, kidney-nourishing, essence-fixing, and psoas-muscle-meridian-strengthening functions. The medicine composition has fast treatment effect, short treatment course, and long-lasting treatment effect against post-stroke limb numbness.

The invention discloses a traditional Chinese medicine for treating post-stroke limb numbness, relating to the technical field of traditional Chinese medicines. The traditional Chinese medicine comprises the 19 raw materials including semen brassicae, rhizoma atractylodis, gastrodia elata, mucuna macrocarpa wallich, radix scrophulariae, Chinese angelica, phyllanthus urinaria, papaya, the root of bidentate achyranthes, astragalus membranaceus, notopterygium root, common andrographis herb, lumbricus, gynostemma pentaphylla, bracketplant, root of rustyhair raspberry, ptyas mucosus, lactarius lignyotus and honey-fried licorice root. The traditional Chinese medicine disclosed by the invention has the good curative effect to post-stroke limb numbness; and furthermore, the traditional Chinese medicine is simple in preparation process, steady in preparation and easy to popularization and application.

The invention discloses traditional Chinese medicine decoction for treating post-stroke hypermyotonia. The traditional Chinese medicine decoction is prepared from the following traditional Chinese medicine raw materials by weight: 30g of radix paeoniae alba, 30g of Chinese angelica, 20g of suberect spatholobus stem, 15g of polygonum multiflorum, 15g of asparagus fern, 20g of radix ophiopogonis, 20g of lycopodium clavatum, 15g of garden balsam stem, 15g of gastrodia elata, 10g of saposhnicovia divaricata, 30g of uncaria, 30g of crude dragon bones, 30g of raw oyster shells, 10g of herba schizonepetae carbon, 10g of leech powder (taking after mixing with water), 30g of salviae miltiorrhizae, 15g of earthworms, 15g of ligusticum wallichii, 30g of root of kudzu vine, 10g of scorpio and 10g of stiff silkworms. According to the invention, the raw materials are matched based on syndrome differentiation to achieve effects of softening tendons, relaxing tendons, relieving convulsion and relieving post-stroke hypermyotonia, has remarkable curative effect to a patient with post-stroke hypermyotonia, and is worthy of clinical popularization.

System and method for monitoring motor recovery in a post-stroke treatment is disclosed. Motor activity data corresponding to limbs movement is collected during an acute stroke period. The motor activity data is transmitted to at least one base station and an activity value for each arm of two arms is calculated in a predefined time window by using the motor activity data. The activity value for each arm is compared thus providing the monitoring of the motor activity.

The invention discloses hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of the hirudo polypeptide, and relates to the fields of traditional Chinese medicine, natural medicine and health care products. The structure of the hirudo polypeptide is presented as a formula I, human umbilical vein endothelial cell expressing vascular hemophilia factor (vWF) and a plasminogen activator inhibitor-1(PAI-1) can be significantly lowered at the low concentration of the hirudo polypeptide, the survival rate of nerve cells after oxygen and glucose deprivationis increased, platelet aggregation in vitro is inhibited, the plasma recalcification time is prolonged, formation of thrombi in vivo is reduced, neurobehavior after cerebral infarction of a rat is improved, encephaledema is relieved, the area of cerebral infarction is reduced, the toxicity is low, good application prospects are achieved, and the hirudo polypeptide can be used for preparing medicine or health care products for treating or adjuvant therapy of cardiovascular and cerebrovascular diseases such as atherosclerosis, thrombi and cerebral post-stroke nerve function deficit. The formulaI is NH2-Leu-D-Leu-Ser-Gly-Val-R whitmantide A: R=D-Leu-Gly-COOHwhitmantide B: R=D-Leu-Gly-Gly-COOH whitmantide C: R=COOH.